Hyaluronic acid pluronic hydrogel for articular cartilage treatment
Summary
USPTO granted Patent US12594297B2 to Medicrinia, Co., Ltd. on April 7, 2026, covering a hydrogel composition of hyaluronic acid and pluronic for preventing or treating articular and cartilage injury. The patent has 9 claims, CPC classifications A61K 31/728, A61K 9/06, A61K 47/36, A61P 19/02, and was filed on August 3, 2020.
What changed
This patent grants Medicrinia, Co., Ltd. exclusive rights to a binder-free hydrogel composition combining hyaluronic acid and pluronic for intraarticular injection to treat cartilage injuries and joint inflammation. The invention provides a long-lasting viscosity supplement with high biocompatibility and no cytotoxicity, designed to remain in the articulation for extended periods due to increased viscoelasticity.
Pharmaceutical and medical device companies developing injectable orthopedic products or viscosupplementation therapies should conduct freedom-to-operate analyses to avoid potential infringement. Competitors seeking to commercialize similar hyaluronic acid-based hydrogel formulations for joint treatment may need to design around this patent or pursue licensing agreements with the patent holder.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition comprising hyaluronic acid and pluronic for preventing or treating articular and cartilage injury
Grant US12594297B2 Kind: B2 Apr 07, 2026
Assignee
Medicrinia, Co., Ltd.
Inventors
Yoo Jin Ha
Abstract
The present invention relates to a hydrogel composition prepared without using a binder. The composition is easy to inject into the human body and has a therapeutic effect on intraarticular lesions and inflammation. The hydrogel of the present invention, which is prepared without a binder, is degraded in an articulation for a long time due to the increased viscoelasticity thereof, thereby enjoying the advantage that the absorption time is prolonged. Therefore, when the hydrogel is used as an injection, its efficacy may be maintained for a long time. Furthermore, the hydrogel has no cytotoxicity, thus showing very high biocompatibility. Particularly when directly injected to an injured site in an articulation, the hydrogel has a therapeutic effect on the intraarticular lesion and inflammation in the corresponding site and thus may be advantageously utilized as a composition for prevention or treatment of an intraarticular lesion and as a viscosity supplement.
CPC Classifications
A61K 31/728 A61K 9/06 A61K 47/36 A61P 19/02
Filing Date
2020-08-03
Application No.
17631680
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.